TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
about
Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".Effects of combined epidural and general anesthesia on intraoperative hemodynamic responses, postoperative cellular immunity, and prognosis in patients with gallbladder cancer: A randomized controlled trial.Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.
P2860
TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
TCR/CD3 activation and co-stim ...... em improve anti-tumor immunity
@en
type
label
TCR/CD3 activation and co-stim ...... em improve anti-tumor immunity
@en
prefLabel
TCR/CD3 activation and co-stim ...... em improve anti-tumor immunity
@en
P2093
P2860
P50
P356
P1433
P1476
TCR/CD3 activation and co-stim ...... em improve anti-tumor immunity
@en
P2093
Anja Feldmann
Anne Gocht
Claudia Arndt
Eva-Maria Ewen
Irene Michalk
Malte von Bonin
Marc Schmitz
Nicole Berndt
Slava Stamova
Stefanie Koristka
P2860
P304
P356
10.4161/ONCI.26770
P577
2013-10-22T00:00:00Z